Argentina: Ministry of Health delivers first batch of medical cannabis for children with refractory epilepsies

Treatment with medicinal cannabis will be intended for 14 patients of Garrahan hospital
August 18, 2021

This post is also available in: Español

The Ministry of Health in Argentina made the first delivery of medical-grade cannabis-based formulations to patients with epilepsy at Garrahan Hospital.

Protected by law 27350, the delivery and care of these patients represents a milestone in ensuring safe treatments for the population of patients with severe seizures who do not have effective treatments. The high-quality oils aim to improve the quality of life of at least 14 patients with seizures associated with the ailments Dravet Syndrome and Lennox Gastaut, among others.

"We are delivering for the first time a domestic cannabis derivative. This is a policy prioritized by the Ministry of Health that will benefit patients who are currently being treated with this product. It is an important day because we have accessibility to treatment, national production and this joint work between the hospitals and the Ministry of Health of the Nation, "said Sandra Tirado, Secretary of Access to Health, when leading the act in the hospital.

Each bottle has 3500 mg in a 30 ml bottle and is intended to meet the demand of such patients for at least the next two to three months. Argentina at the forefront of medicinal cannabis Argentine public institutions have understood the need for the development, research and treatment of their population with this type of novel remedies. Not only is there great scientific validity, but also, new types of treatment must be promoted and strengthened, in accordance with public policy.

This decision also puts Argentina at the forefront of the waste and acceptance of cannabinoids. According to Marcelo Morante, coordinator of the Medical Cannabis Program of the National Health portfolio, state involvement is the ideal path.

"It is the ideal scenario to conduct these processes: the Present State approaching positions from the scientific society and the mother who cultivates, finding these spaces of safety and efficiency that is the path that will lead us to what we seek that is the improvement of this pathology that so much incapacitates".

For his part, the head of the Neurology Service of the hospital, Roberto Caraballo, indicated that "in these children who present frequent or daily seizures, some of them severe, it conditions the quality of life of the patient and the family, therefore the use of this treatment is important to control the crises, to reduce them and thus favor a better quality of life of the child and the family. That's the fundamental indication of this new therapeutic product."

The drug is called "Convupidiol" and was created in a national laboratory with raw material brought from Switzerland. For their part, hospital researchers have some time using treatments of this type and checking the effectiveness of these.

This post is also available in: Español

Escrito por: Redacción
Publicado en la revista 
SíGUENOS EN INSTAGRAM COMO @MCNGLOBAL

"La aprobación del proyecto de cáñamo y cannabis medicinal es un avance fundamental en el reconocimiento del derecho a la salud con un altísimo potencial económico para las zonas rurales. ¡Sí se pudo!", José María Villalta ...

Mi abuela después de enterarse de que legalizaron el cannabis medicinal en Costa Rica. 😆😆 ...

#LeyCannabisMedicinalCostaRica 🇨🇷🇨🇷🇨🇷🇨🇷 ...

Esta tarde la Asamblea Legislativa de Costa Rica aprobó en primer debate el proyecto de ley que permitirá el cultivo, comercio, siembra y distribución de cannabis.

El proyecto de Ley 21.88 fue votado positivamente por 33 legisladores y rechazado por 13.

El principal planteamiento de este proyecto es habilitar la producción nacional mediante a una legislación que permite sembrar estas plantas en suelo nacional y ser aprovechadas en diferentes industrias como la agrícola, farmacéutica, y comercial mediante al control estatal.

Con el impuesto del 1% de las utilidades a quienes se dedique a esta actividad, el Ministerio de Salud, Seguridad y Agricultura podrán tener recursos para investigación, control de cultivos ilegales y brindar asesorías.

Otro de las características positivas es que por ley se deberá de brindar el 40% del negocio a empresas locales, medianas, pequeñas y microempresas. Ese repercutirá para que centros agrícolas, grupos indígenas, cooperativas y otro tipo de grupos puedan ser parte de la industria para la cual se necesitan grandes capitales de inversión.

El plan tiene la intención de generar réditos económicos, pero además de ser una nueva alternativa de salud para miles de costarricenses con padecimientos como el cáncer, epilepsia, inflamaciones crónicas, dolores crónicos, enfermedades neurodegenerativas y por su valor nutricional.

Cáñamo tendrá un límite de 1% y las semillas de cannabis psicoactivo se importará, comercializará de manera legal. Asimismo, cada licencia para cannabis medicinal tendrá una validez del 6 año.

Este jueves se discutirá el proyecto en segundo debate para su final aprobación.

Link en Bio.
-
#cannabis #cáñamo #legalización #CostaRica #Hemp #Sostenibilidad #Villalta #ZoilaVolio #AsambleaLegislativa 🍃
...

Lo más reciente en MCN

También te puede interesar

September 23, 2021
First hemp and CBD boutique store opens in Costa Rica

Hemp concept stores are booming in the United States, Europe and arrives for the first time in Costa Rica

Ver Artículo
August 18, 2021
Argentina: Ministry of Health delivers first batch of medical cannabis for children with refractory epilepsies

Treatment with medicinal cannabis will be intended for 14 patients of Garrahan hospital

Ver Artículo
August 11, 2021
Hemp could create batteries three times stronger than lithium batteries

Researchers believe cars and power tools can take advantage of hemp batteries

Ver Artículo
July 29, 2021
Survey: Patients say CBD helps them reduce pain

Most participants – 59% – said these products helped them with pain

Ver Artículo
Copyright Zegreenlab S.A. Todos los derechos reservados © 2020. Hecho en Costa Rica.
Diseño & Desarrollo por Dbugger Studio
Argentina: Ministry of Health delivers first batch of medical cannabis for children with refractory epilepsiesArgentina: Ministry of Health delivers first batch of medical cannabis for children with refractory epilepsiesArgentina: Ministry of Health delivers first batch of medical cannabis for children with refractory epilepsiesArgentina: Ministry of Health delivers first batch of medical cannabis for children with refractory epilepsies Argentina: Ministry of Health delivers first batch of medical cannabis for children with refractory epilepsies Argentina: Ministry of Health delivers first batch of medical cannabis for children with refractory epilepsies Argentina: Ministry of Health delivers first batch of medical cannabis for children with refractory epilepsies Argentina: Ministry of Health delivers first batch of medical cannabis for children with refractory epilepsies Argentina: Ministry of Health delivers first batch of medical cannabis for children with refractory epilepsies Argentina: Ministry of Health delivers first batch of medical cannabis for children with refractory epilepsies Argentina: Ministry of Health delivers first batch of medical cannabis for children with refractory epilepsies Argentina: Ministry of Health delivers first batch of medical cannabis for children with refractory epilepsies Argentina: Ministry of Health delivers first batch of medical cannabis for children with refractory epilepsies Argentina: Ministry of Health delivers first batch of medical cannabis for children with refractory epilepsies Argentina: Ministry of Health delivers first batch of medical cannabis for children with refractory epilepsies Argentina: Ministry of Health delivers first batch of medical cannabis for children with refractory epilepsies Argentina: Ministry of Health delivers first batch of medical cannabis for children with refractory epilepsies Argentina: Ministry of Health delivers first batch of medical cannabis for children with refractory epilepsies